Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb 25;15(1):17-20.
doi: 10.1002/cld.833. eCollection 2020 Jan.

An Interaction Between Glecaprevir, Pibrentasvir, and Colchicine Causing Rhabdomyolysis in a Patient With Chronic Renal Disease

Affiliations
Review

An Interaction Between Glecaprevir, Pibrentasvir, and Colchicine Causing Rhabdomyolysis in a Patient With Chronic Renal Disease

Dawn S Harrison et al. Clin Liver Dis (Hoboken). .
No abstract available

PubMed Disclaimer

References

    1. Rein DB, Smith BD, Wittenborn JS, et al. The cost‐effectiveness of birth‐cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med 2012;156:263‐270. - PMC - PubMed
    1. McGarry LJ, Pawar VS, Panchmatia HR, et al. Economic model of a birth cohort screening program for hepatitis C virus. Hepatology 2012;55:1344‐1355. - PubMed
    1. Davis GL, Alter MJ, El‐Serag H, et al. Aging of hepatitis C virus (HCV)‐infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010;138:513‐521.e6. - PubMed
    1. Smolders EJ, Berden FAC, de Kanter CTMM, et al. The majority of hepatitis C patients treated with direct acting antivirals are at risk for relevant drug‐drug interactions. United European Gastroenterol J 2017;5:648‐657. - PMC - PubMed
    1. Afdhal NH. Fibroscan (transient elastography) for the measurement of liver fibrosis. Gastroenterol Hepatol 2012;8:605‐607. - PMC - PubMed